Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.13 +0.27 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
7 Blue-Chip Cash Cows to Milk for Steady Income
Sometimes, you want to weather the storm rather than risk everything. For that, blue-chip income stocks can help. 
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
Assessing Johnson &amp; Johnson's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Analyzing JOHNSON & JOHNSON (NYSE:JNJ)'s Dividend Potential. 
Via Chartmill
7 Safe Haven Stocks to Buy Before the Next Market Correction
Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail. 
Via InvestorPlace
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
Via Benzinga
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
A federal judge has dismissed a Johnson & Johnson subsidiary's lawsuit against Dr. Jacqueline Moline, who linked talc products to cancer. The ruling supports Moline's research and free speech rights... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
JNJ Should Rally Soon Or See 3 Swings Higher At Least
Johnson & Johnson (JNJ​​​​​​​) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. 
Via Talk Markets
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best and worst performers. 
Via Benzinga
Topics Stocks
Exposures US Equities
"Rule Breaker Investing" Mailbag: Talking Stocks and Options
We also talk with Sean Milliken, managing director of The Motley Fool Foundation’s ImpactFool (IF) Fund. 
Via The Motley Fool
3 Retirement All-Stars for Steady Growth and Income
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement. 
Via InvestorPlace
Topics Retirement
Exposures Pension
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Explore three high-yield dividend stocks that not only offer yields of 3% or more but also boast multiple decades of payout growth. 
Via InvestorPlace
Judge Blocks Cancer Victims' Attempt To Stop Johnson & Johnson Bankruptcy Plan
A federal judge rejected a bid by cancer victims to block Johnson & Johnson from pursuing a $6.48 billion bankruptcy settlement for talc-related lawsuits, stating potential harm was "strictly... 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
The market previously supported a higher multiple for these undervalued stocks, making them attractive contrarian targets. 
Via InvestorPlace
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice. 
Via InvestorPlace
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Income-seeking investors can find plenty of opportunities in any market environment. 
Via The Motley Fool
4 Cheap Stocks to Buy in July
All four of these stocks are trading at very intriguing valuations. 
Via The Motley Fool
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe. 
Via Talk Markets
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
From Beasley Allen
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
2 Incredible Dividend Growth Stocks to Buy Right Now
These two dividend growth stocks can level up your portfolio. 
Via The Motley Fool
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company. 
Via The Motley Fool
The 3 Smartest Dow Stocks to Buy With $1000 Right Now
Explore why these three well-known Dow stocks to buy are well worth your next $1,000 investment to grow your portfolio. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.